Navigation Links
Harmful chemicals may reprogram gene response to estrogen

differently.

"This study is telling us that an environmental reprogramming of a normal response, combined with an inherited gene defect, work together to promote cancer," said NIEHS Director David Schwartz, M.D. "If this model is correct, it will help doctors to determine which individuals are more likely to develop cancers of the uterus, breast and prostate."

The finding should alert doctors to ask more questions about a patient's early-life exposures to chemicals and other harmful agents in order to better predict that person's cancer risk.

"Most people with a family history for a particular disease are concerned about their recent exposures to harmful agents in the environment," said Cheryl Walker, Ph.D., professor of molecular carcinogenesis at the M.D. Anderson Cancer Center and lead author on the study. "We are just beginning to realize that exposures received decades earlier, during critical developmental stages, may be much more important in determining who develops cancer as an adult."

The researchers used a special strain of rats with a defect in a gene called Tsc-2 (tuberous sclerosis complex 2) that made them more susceptible to uterine leiomyomas, benign tumors that are common in women over 30 years of age. These rats were then treated with DES during days 3, 4 and 5 of life, during a critical period of uterine development.

Once the rats reached adulthood, almost 95 percent had developed the uterine tumors. Furthermore, the tumors were much larger and more numerous than those in genetically defective rats not receiving the DES treatment. "These data suggest that environmental exposures during development of the uterus can interact with a preexisting genetic susceptibility to increase the risk of disease," said Walker. "We are looking at a new kind of gene-environment interaction that determines who gets cancer and who doesn't."

According to Walker, the increase in frequency and size of the uterine tumors
'"/>

Source:NIH/National Institute of Environmental Health Sciences


Page: 1 2 3

Related biology news :

1. Harmful Bacterium Commonly Found in Poultry May Survive Refrigeration and Frozen Storage Combined
2. Research Reveals Functions Of Harmful Shellfish Pathogens
3. Harmful Algal Blooms monitored from space in Chile
4. Two chemicals boost immune cells ability to fight HIV without gene therapy
5. Pittsburgh researchers discover that certain chemicals in the blood may indicate brain injury
6. A silent pandemic: Industrial chemicals are impairing the brain development of children worldwide
7. Enhancing activity of marijuana-like chemicals in brain helps treat
8. Poplar trees redirect resources in response to simulated attack
9. A comprehensive response to HIV could prevent 10 million AIDS deaths in Africa by 2020
10. Scientists solve structure of key protein in innate immune response
11. Mouse with designer liver has enhanced glucose tolerance, insulin response
Post Your Comments:
Breaking Biology Technology:Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2